OncoSec Medical Inc IPO year
What is the IPO year of OncoSec Medical Inc?
The IPO year of OncoSec Medical Inc is 2011
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on NASDAQ compared to OncoSec Medical Inc
What does OncoSec Medical Inc do?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Companies with ipo year similar to OncoSec Medical Inc
- Goldman Sachs Mutual Fund - Goldman Sachs Nifty Exchange Traded Scheme has IPO year of 2010
- Software Effective Solutions has IPO year of 2010
- GINSMS has IPO year of 2010
- Photonike Capital SA has IPO year of 2010
- Parabolic Drugs has IPO year of 2010
- West Kirkland Mining has IPO year of 2010
- OncoSec Medical Inc has IPO year of 2011
- Omineca Mining and Metals has IPO year of 2012
- iShares Asia Trust - iShares Core CSI 300 Index ETF has IPO year of 2012
- Wendy`s Co has IPO year of 2012
- Unisys has IPO year of 2012
- Christopher & Banks has IPO year of 2012
- Wellesley has IPO year of 2012